Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897535 | 0.92 | POLB (0.50) | POLBMEN1KMT2AGAAALOX12 | |
| SCHEMBL5180943 | 0.92 | POLB (0.52) | POLBMEN1KMT2AGAAALOX12 | |
| SCHEMBL5180947 | 0.92 | POLB (0.52) | POLBMEN1KMT2AGAAALOX12 | |
| SCHEMBL17452430 | 0.86 | RRM1 (0.58) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL5180335 | 0.86 | MAPT (0.58) | MEN1KMT2AGAANPSR1NPC1 | |
| SCHEMBL5180324 | 0.86 | MAPT (0.58) | MEN1KMT2AGAANPSR1NPC1 | |
| SCHEMBL5180795 | 0.84 | GFER (0.64) | POLBGAANPSR1RAB9AMAPT | |
| SCHEMBL5180504 | 0.84 | GFER (0.64) | POLBGAANPSR1RAB9AMAPT | |
| SCHEMBL17452410 | 0.84 | NPC1 (0.50) | NPC1RAB9AMAPTPKM | |
| SCHEMBL5180097 | 0.83 | MAPT (0.52) | POLBKMT2AALOX12NPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016930-A1 | PROTECTIVE MOLECULES AGAINST ANTHRAX TOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016930-A1 | PROTECTIVE MOLECULES AGAINST ANTHRAX TOXIN | ANTXR2, TSG101, ANXA1 | POLB 1959/4885MEN1 4291/4885KMT2A 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.